BioSpace News Archive

Arbitrator Finds Kaiser Foundation Health Plan Inc Violated Patient’s ADA Rights

Gilead will have exclusive rights to Lyndra’s platform for HIV therapies

Clinical study data on switching haemophilia A and B patients from on-demand treatment to extended half-life prophylaxis showed a positive impact on clinical outcomes, with improvements in quality of life and reduced annual bleeding rates.

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced that it has entered into a non-exclusive license and collaboration agreement with Roche.

Exact Sciences Corp. announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results.

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has accepted for review six supplemental Biologics License Applications to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include an every-six-weeks dosing schedule option.

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc., announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company’s eye vitamin portfolio.

Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types

Lead Clinical Candidate Targeting SHP2 Currently in Phase 1/2 Clinical Program for Tumors with Specific Oncogenic Mutations

Healthcare organization looks to gain better reporting and insights to identify gaps in evidence, reduce care variations between facilities